Back to Awarded Treatment Trials


Awarded Trial: 03T-457

Grant ID

03T-457

Illness

Bipolar Disorder

Primary Drug/Intervention

Riluzole

Primary Dosage

up to 200 mg/day

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Payne

Sample Size

94

Duration of Study Period for Each Subject

8 weeks

Outcome Measurements

MADRS, YMRS, HAM-D, CGI

Results

Ninety-four (94) patients with BP I or II, depressed phase, without psychotic features, were randomized to riluzole 200 mg/d or placebo for 8 weeks. Riluzole decreases the release of glutamate and has been used in the treatment of amyotrophic lateral sclerosis. Assessment was with YMRS, MADRS, and CGI. Both groups improved, with the placebo group doing somewhat better than the riluzole group. Thus, it is a clean negative study.

Publication

N/A

Link

N/A

PI Name

Jennifer Payne

Degree

MD

Center

Department of Psychiatry

Institution

The Johns Hopkins University

Address

600 N. Wolfe Street, Meyer 3-165

City or Town

Baltimore

State or Province

MD

Zip or Postal Code

21287

Country

USA

Email Address

jpayne5@jhmi.edu